AUSTIN - Volition Rx Limited (NYSE AMERICAN: VNRX) ('Volition') today provided an update on its Nu Q Clinical Assays which use a magnetic particle-based assay format.

Volition has completely re-engineered its Nu.Q assays leading to a step-change improvement in analytical performance. Volition expects this enhanced analytical performance to translate into improved clinical performance in the studies to be carried out and reported in the coming months.

Relative to Volition's ELISA plate Nu.Q assay format, the magnetic particle-based assay format demonstrates: A 10-20-fold improvement in analytical sensitivity of the assays.

Typical within-day reproducibility of quantitative test results below 3% (previously

(C) 2020 Electronic News Publishing, source ENP Newswire